Teva has supply chain issues in Russia; U.S. track-and-trace law up for approval;

@EricPFierce: Manufacturing, sanitation issues at Sanofi's Toronto vaccine plant has been a problem for some time now. Story | Follow @EricPFierce

> Authorities in Russia say that Teva Pharmaceutical Industries ($TEVA) has had inconsistent deliveries there of its multiple sclerosis drug Copaxane and carboplatin, a generic cancer drug. Story

> The U.S. Senate is poised to pass legislation, already approved by the U.S. House, that will lead to track-and-trace of individual drug units in the U.S. Story

> West Pharmaceutical Services in its third-quarter earnings projected revenue growth of 6% to 8% for the year. Release

> The FDA will add injectable drugs to the list of drugs that manufacturers must report in the event that they expect shortages. Story (sub. req.)

> An Indian authority has rejected a request from Mumbai-based BDR Pharmaceuticals for a compulsory license to manufacture a generic of Bristol-Myers Squibb's ($BMY) cancer drug Sprycel. Story

And Finally... GlaxoSmithKline ($GSK) has partnered with the Bill & Melinda Gates Foundation on a $1.8 million project to develop vaccines that are heat resistant, requiring less refrigeration to be used in developing countries where cold chain delivery is difficult. Story